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Abstract.  Hypomethylating  drugs  are  useful  and  have  been  approved  for  the  treatment  of 
myelodysplastic syndromes (MDS) and Chronic Myelomonocytic Leukemia  (CMML). However, 
phase 2 and 3 studies that assessed these agents in MDS, have included o
patients with CMML, and there are just a few specific reports on CMML patients.
is actually authorised for the treatment of CMML patients with 10
myeloproliferative disorder, who are not eligible for haematopoietic stem cell transplantation. This 
hypomethylating agent in MDS is known for causing transient cytopenias, most often occurring 
during the first 2 cycles. Here we report a case of an atypical delayed and prol
toxicity  during  Azacitidine  treatment  in  a  CMML  patient;  furthermore  we  also  reviewed  the 
literature regarding the efficacy of the drug and the management of hematologic adverse effects, in 
term of dose adjustments or alternative schedule
Introduction. CMML  is  a  clonal  disorder  of 
haematopoietic  stem  cell,  often  occurring  in  elderly 
patients,  sharing  heterogeneous  clinical  and 
morphological  features  of  both  MDS  and  chronic 
myeloproliferative disorders (MPD). Originally it was 
classified  by  the  French-American
working  group  as  a  myelodysplastic  syndrome 
characterized  by  monocytosis (>  1000/microl),  bone 
marrow  (BM)  monocyte  infiltration,  blast  cells  less 
than 5% in the peripheral blood (PB) and less than 30% 
in  the  BM.
1 CMML  has  been  reclassified  and  it  is 
currently  included  in  the 
Myelodysplastic/Myeloproliferative  Neoplasms 
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Hypomethylating  drugs  are  useful  and  have  been  approved  for  the  treatment  of 
myelodysplastic syndromes (MDS) and Chronic Myelomonocytic Leukemia  (CMML). However, 
phase 2 and 3 studies that assessed these agents in MDS, have included o
patients with CMML, and there are just a few specific reports on CMML patients.
is actually authorised for the treatment of CMML patients with 10-29% marrow blasts without 
disorder, who are not eligible for haematopoietic stem cell transplantation. This 
hypomethylating agent in MDS is known for causing transient cytopenias, most often occurring 
during the first 2 cycles. Here we report a case of an atypical delayed and prol
toxicity  during  Azacitidine  treatment  in  a  CMML  patient;  furthermore  we  also  reviewed  the 
literature regarding the efficacy of the drug and the management of hematologic adverse effects, in 
term of dose adjustments or alternative schedule of administration, in specific CMML setting.
CMML  is  a  clonal  disorder  of 
often  occurring  in  elderly 
sharing  heterogeneous  clinical  and 
morphological  features  of  both  MDS  and  chronic 
Originally it was 
American-British  (FAB) 
working  group  as  a  myelodysplastic  syndrome 
(>  1000/microl),  bone 
marrow  (BM)  monocyte  infiltration,  blast  cells  less 
than 5% in the peripheral blood (PB) and less than 30% 
CMML  has  been  reclassified  and  it  is 
currently  included  in  the 
Myelodysplastic/Myeloproliferative  Neoplasms 
(MDS/MPN) category in the new WHO classification. 
Particularly,  this  classification  subdivides  CMML  i
two subclasses according to the prognosis: 
with 5-9% BM blasts and <5% PB blasts and CMML
with 10-19% BM blasts and/or 5
WBC  of  13  x 10
9/l  or  greater  identifies 
myeloproliferative variant of CMML (MPD
whereas a lower white blood cell count (WBC) defines 
a myelodysplastic variant of CMML (MDS
CMML  is  a  very  hard  disease  to  treat  and  the 
prognosis  of  the  elderly  is  quite  v
approximately  2.5-year  median  survival
age and comorbidities impact on survival, making bone 
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Hypomethylating  drugs  are  useful  and  have  been  approved  for  the  treatment  of 
myelodysplastic syndromes (MDS) and Chronic Myelomonocytic Leukemia  (CMML). However, 
phase 2 and 3 studies that assessed these agents in MDS, have included only a small number of 
patients with CMML, and there are just a few specific reports on CMML patients. The Azacitidine 
29% marrow blasts without 
disorder, who are not eligible for haematopoietic stem cell transplantation. This 
hypomethylating agent in MDS is known for causing transient cytopenias, most often occurring 
during the first 2 cycles. Here we report a case of an atypical delayed and prolonged hematologic 
toxicity  during  Azacitidine  treatment  in  a  CMML  patient;  furthermore  we  also  reviewed  the 
literature regarding the efficacy of the drug and the management of hematologic adverse effects, in 
of administration, in specific CMML setting.
PN) category in the new WHO classification. 
Particularly,  this  classification  subdivides  CMML  in 
two subclasses according to the prognosis: CMML-1 
9% BM blasts and <5% PB blasts and CMML-2 
19% BM blasts and/or 5-19% PB blasts.
2 A 
/l  or  greater  identifies 
myeloproliferative variant of CMML (MPD-CMML), 
whereas a lower white blood cell count (WBC) defines 
a myelodysplastic variant of CMML (MDS-CMML).
3
CMML  is  a  very  hard  disease  to  treat  and  the 
prognosis  of  the  elderly  is  quite  variable,  with  an 
year  median  survival.
4 Advanced 
age and comorbidities impact on survival, making bone Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
marrow  transplantation  seldom  possible.  Patients  are 
usually  treated  with  supportive  care  or  mild 
cytoreductive therapy (Etoposide, Hydroxyurea or low-
dose Cytarabine), until leukemic evolution.
1 In the era 
of  epigenetics  therapy,  new  molecular  targeted 
therapies offer the chance to modify the natural history 
of  this  disease.  Among  these,  the  hypomethylating 
agents Azacitidine
5 and Decitabine
6 have been shown 
to induce responses in CMML. Pooled Azacitidine and 
Decitabine  published  studies  in  MDS  suggest  an 
overall  response rate of 39% to  45% and an overall 
survival (OS) benefit for responders. However, CMML 
patients included in these series, represented a minority 
of the population.
7,8
Since 2008 Azacitidine has been authorised in the 
European Union for the treatment of CMML patients 
with  10-29%  marrow  blasts,  without 
myeloproliferative  disorder,  who  are  not  eligible  for 
haematopoietic stem cell transplantation.
9-10
Azacitidine  in  MDS  is  known  for  causing 
cytopenias, most often occurring in the first 2 cycles. 
Generally, these hematologic adverse events decrease 
during subsequent cycles and are usually managed with 
dosing  delays  (23-29%).
11 However,  the  activity  of 
Azacitidine  has  been  investigated  in  trials  primarily 
designed to test the efficacy and safety of the drug for 
the treatment of MDS.
7 Only a few reports analyzed 
the use of Azacitidine in specific CMML subset and 
there  are  no  prospective  studies  with  a  sufficient 
number of patients affected by this disease.
5,8
Here we report a case of an atypical delayed and 
prolonged  hematologic  toxicity  during  Azacitidine 
treatment in a patient affected by CMML; furthermore 
we also reviewed the literature regarding the efficacy 
of  the  drug  and  the  management  of  hematologic 
adverse  effects,  in  term  of  dose  adjustments  or 
alternative  schedule  of  administration,  in  specific 
CMML setting.
Case Report. In November 2007 a 64-year old man 
was referred to our hospital with leucocytosis, anemia 
and asthenia. Comorbidities included hypertension and 
diabetes  mellitus.  At  presentation,  PB  count  showed 
Hemoglobin  (Hb)  level  of 10.7  g/dl,  WBC  count  of 
42.57  x  10
9/l  (4.25  x  10
9/l  monocytes)  and  platelet 
(PLT)  count  of  214  x  10
9/l.  Physical  examination 
revealed mild hepatomegaly (3 cm below costal arch), 
significant splenomegaly (8 cm below costal arch), no 
peripheral  lymphoadenopathy.  Abdominal  ultrasound 
imaging  confirmed  increased  liver  size  with 
dyshomogeneous  pattern  without  focal  lesions  and 
markedly  increase  of  spleen  size  with  longitudinal 
diameter of 21 cm. Laboratory tests, to evaluate renal 
and  liver functions,  were  normal.  BM  aspirate  and 
biopsy  were  performed  showing  hypercellular  bone 
marrow  with  increased  number  of  monocytes,  a 
variable degree of dysplasia in all three lineages, with 
3%  of  marrow  blasts.  Cytogenetic  analysis  showed 
normal karyotype; JAK2V617F and bcr/abl assessment 
were  negative.  c-Kit  exon  8  and  17  mutations  and 
PDGFR  alfa/beta  rearrangement  were  also  negative. 
TET2  mutational  tests  had  not  been  performed, 
because still not available in our laboratory. According 
to  these  assessments, the  patient  was  diagnosed as 
MPD-CMML-1.
The  patient  had  been  initially  treated  with 
Hydroxyurea, later associated with recombinant human 
erythropoietin  for  Hb  decrease,  obtaining  a  transient 
response. In July 2009 anemia quickly worsened (Hb 
5.7  g/dl)  and  he  became  transfusion  dependent. 
Concurrently,  the  patient  developed  a  progressive 
leucocytosis  (WBC  64.48  x  10
9/l):  BM  aspirate  was 
performed, showing an  increased  number of  marrow 
blasts  (11%),  diagnostic  for  MPD-CMML-2.  A 
combined  therapy  with  6-Mercaptopurine  and 
Hydroxyurea was started, with a transient response on 
WBC  count  but  not  on  anemia.  In  fact,  transfusion 
requirement significantly increased until July 2010: at 
that time blood counts displayed severe anemia (Hb 6.7 
g/dl),  normal  WBC  count  (3.85  x  10
9/l,  monocyte 
count  0,47  x  10
9/l)  with  PLT  count  of  144  x  10
9/l. 
Therefore  we  decided  to  stop  ongoing  cytoreductive 
treatment  and  to  start  the  epigenetic  therapy  with 
Azacitidine after 15 days. The drug was administered 
subcutaneously  at  the  approved  schedule  of  75 
mg/m
2/day  for  7  days  every  28  days  (AZA  5-2-2 
regimen).
10 The  patient  progressively  lost  his 
transfusion dependence and obtained a partial response 
after  4  cycles,  according  to  International  Working 
Group Criteria:
12 Hb level, WBC and PLT count were 
11.1 g/dl, 10.61 x 10
9/l and 167 x 10
9/l, respectively. 
Absence of blast cells with slight degree of trilineage 
dysplasia  was  documented  in  BM  revaluation  in 
October  2010. Physical examination  revealed  a  mild 
reduction  of  splenomegaly,  confirmed  also  by  the 
abdominal ultrasound (spleen longitudinal diameter: 18 
cm). No hematologic toxicity was reported in the first 
four cycles. 
In  November  2010  the  patient  started  the  fifth 
Azacitidine  cycle  and  he  unexpectedly  developed  a 
severe and prolonged hematologic toxicity: on day +32 
blood count displayed a serious degree of anemia (Hb 
6.3  g/dl,  leading  to  a  new  transfusion  requirement), 
mild  leucopenia  (WBC  1.2  x  10
9/l  with  absolute 
neutrophil  count  of  0.54  x  10
9/l)  and  severe 
thrombocytopenia  (PLT  7  x  10
9/l).  BM  aspirate  and 
biopsy  on  day  +  48 excluded  a  leukemic 
transformation,  showing  10%  of  cellularity,  rare 
CD34+  cells  and  features  highly  suggestive  of  a 
therapy  related  bone  marrow  hypoplasia.  Viral Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
infections  were  also  excluded:  serological  test  for 
Cytomegalovirus  (CMV),  Ebstein-Barr  Virus  (EBV), 
Parvovirus B19, Enterovirus, Adenovirus, Herpes virus 
1-2, Hepatitis B (HBV), Hepatitis C (HCV) and HIV 1-
2  were  negative.  Transfusion  support  had  been 
immediately  started  and  granulocyte  colony 
stimulating factor (G-CSF)  was administered starting
from day +49, because of lack of neutrophils recovery. 
Slow  hematologic  improvement  was  observed  from 
day +62 and hematologic toxicity partially recovered 
from day +71; at day +90 the patient showed resolution 
of  neutropenia  (WBC  5.2  x  10
9/l  with  absolute
neutrophil count of 1.94 x 10
9/l), a partial recovery of 
PLT count (PLT 132 x 10
9/l) and a persistent severe 
transfusion  dependent  anaemia  (Hb  7.3  g/dl). 
Monocyte  count  was  2.14  x  10
9/l.  Antibiotic  and 
antiviral  prophylaxis  were  administered  during  this 
prolonged cytopenia and the patient didn’t experience 
any  infective  complications.  The  treatment  with 
Azacitidine was definitively stopped. 
After 120 days from the last Azacitidine cycle, an 
increasing monocytosis (4.2 x 10
9/l) in PB reappeared, 
suggesting a  progression  of  CMML.  Concomitant 
increase in spleen size was observed (25 cm ultrasound 
longitudinal diameter, with signs of secondary portal 
hypertension). A final attempt of reintroduction of low-
dose  Azacitidine  (one  third  of  the  initial  dose)  was 
performed  for  3  cycles,  without  significant 
hematologic  improvement.  The  patient  died  in  July 
2011 because of gastrointestinal hemorrhage, due to an 
esophageal variceal rupture.
Discussion. The efficacy of Azacitidine and Decitabine 
for  the  treatment  of  MDS  has  been  confirmed  by 
several  national  and  international  clinical  trials.
7-9,12
These  studies  proved  efficacy  of  hypomethylating 
agents compared to  best supportive care. Azacitidine 
significantly  prolongs  median  time  to  progression  to 
acute  myeloid  leukemia  and  improves  median  OS, 
compared  to  conventional  care  regimens.
9-10
Hypomethylating agents have been used in CMML, but 
there are no prospective studies with sufficient number 
of patients with this disease.
5,8
It is known from literature, that Azacitidine-related 
cytopenias in MDS are generally transient (median 14-
16  days)  and  mainly  reported  during  the  first  1-2 
cycles,  decreasing  in  frequency  thereafter.  To  those 
patients,  who  develop  “early  cytopenias”,  it  is 
recommended  to  continue  Azacitidine  therapy  after 
neutrophil  recovery:  responder  patients  may  develop 
hematologic improvement  and benefit from extended 
treatment, until disease progression. In fact, due to the 
reversible effects of hypomethylating agents and to the 
lack  of  eradication  of  the  malignant  clone,  the 
treatment  should  be  continued  until  response 
persists.
14,15 It  is  highly  recommended  to  delay  the 
therapy in case of hematologic toxicity by one or two 
weeks; Azacitidine dose adjustments are scheduled in 
some  selected  cases,  according  to  blood  counts 
observed at the beginning of the subsequent cycle. No 
irreversible cytopenias have been reported so far.
11,14
Of note, the best treatment schedule of Azacitidine 
in CMML patients is still controversial, with few data 
regarding the incidence of adverse events, particularly 
concerning long term hematologic toxicity. For the first 
time,  Costa  et  al.
5 recently  reported  their  experience 
concerning Azacitidine treatment in a selected group of 
37  patients  affected  by  MPD-CMML  and  MDS-
CMML; their data confirmed encouraging activity of 
Azacitidine in CMML setting with an overall response 
rate (ORR) of 39%, showing a lower response rate and 
a lower OS in MPD-CMML compare to MDS-CMML 
patients (ORR 32% versus 55%; OS 12 months versus 
23  months,  respectively). The  drug has  been  overall 
well tolerated with an acceptable hematologic and non-
hematologic toxicity in most of the patients: 9 patients 
experienced some type of cytopenia, always transient. 
No significant differences have been shown in MDS 
and MPD-CMML variants, in terms of major adverse 
events; indeed prolonged hematologic toxicity was not 
reported.  In  this  study,  Costa  et  al.
5 proposed  a 
reduction  of  Azacitidine  dosage  in  a  subgroup  of  9 
patients (25%): a schedule of 100 mg/m
2/day for 5 days 
(AZA 5) has been tested and resulted more convenient 
and equal in efficacy.
8
In the last two years, various gene mutations were 
identified in CMML,
16,17 although none specific for the 
disease. For example, the presence of TET2 mutations 
seems to predict a higher response rate to Azacitidine 
in MDS, although this does not result to a sure benefit 
in  response  duration  or  survival.  The  prognostic 
impact, in term of a better outcome for CMML patients 
whit TET2 mutations, still has to be determined and 
remains controversial.
17
According  to  these  considerations,  our  patient 
obtained a partial hematologic response to Azacitidine 
treatment  with  conventional  schedule,  according  to 
IWG  criteria;
12 he  gained  transfusion  independence 
without  any  hematologic  toxicity  during  the  first  4 
cycles  of  therapy.  Surprisingly,  after  cycle  5  he 
developed 90 days of severe and delayed bone marrow 
hypoplasia,  conditioning  drug  withdrawal.  The  drug 
was  subsequently used  with  dose  reduction  at  the 
progression  of  disease,  without  any  hematologic 
response.  In  our  opinion,  this  atypical  delayed  and 
prolonged  hematologic  effect,  is  not  within  a 
predictable range of toxicity of the drug.
11,14-15
We  could  suppose  that  previous  multiple 
cytoreductive  treatments  have  led  to  a  greater 
sensitivity  to  the  hypomethylation  and  the  cytotoxic Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
effect  of  the  drug. In  fact,  many  CMML-patients, 
unlike  MDS  ones,  who  receive  Azacitidine  without 
previous cytoreductive therapy, are usually pre-treated. 
Therefore, an alternative dosing schedule for CMML 
patients  might  be  needed,  particularly  for  the 
maintenance treatment for those patients, who achieved 
any  hematologic  response during  the  first  4  cycles. 
Maybe a reduction in the daily dose or in days of the 
drug infusion might be a possible solution, in order to 
reduce the hematologic toxicity rate. 
Moreover only few reports have recently assessed 
the efficacy and safety of alternative dosing schedules 
of  Azacitidine  in  MDS  and  CMML,  without 
compromising the efficacy and the tolerability of the 
drug compared to the approved schedule.
5,8,18-19
Lyons et al.
18 evaluated the safety and efficacy of 
three  alternative  Azacitidine  dosing  schedules  in 
MDS/CMML patients (AZA 5-2-2 at 75 mg/m2 for 7 
days, AZA 5 -2 -5 at 50 mg/m2 for 10 days, AZA 5 at 
75 mg/m2 for 5 days - every 4 weeks). Hematologic 
improvement  was similar in  the  three arms  (44%  vs 
45% vs 56%, in the AZA 5-2-2, AZA 5-2-5 and AZA 
5,  respectively).  Moreover,  the  incidence  of  adverse 
events  and  hematologic  toxicity  was  84%,  77%  and 
58%,  in  the  AZA  5-2-2,  AZA  5-2-5  and  AZA  5, 
respectively.  More  patients  in  the  AZA  5  arm 
completed six  cycles of treatment (64%) than in  the 
AZA 5-2-2 (44%) and AZA 5-2-5 (49%).  Bergua et 
al.
19 analyzed the results of AZA 5 schedule in patients 
with  high-risk  MDS  and  acute  myeloid  leukemia 
refractory  to  conventional  therapy. They  concluded 
that 5 days of therapy seems as effective as 7 days in 
this unfavourable setting.
Therefore dose adjustments in term of daily dose or 
in  days  of  the  drug  infusion  could  be  proposed,  for 
example, in pretreated CMML patients, as our case .
To  our  knowledge,  no  similar  prolonged 
hematologic  adverse  events  have been  previously 
reported in literature, suggesting the need of more data,
to better define the optimal timing, the best schedule of
drug administration and the correct management of a 
prolonged  therapy  with  Azacitidine,  in  CMML 
patients. 
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